Merck & Co. (MRK) Free Cash Flow Analysis: Inside an $18B Pharmaceutical Cash Generator

FCF Performance Summary

FCF Quality Score: 8/10

The OCF/Net Income ratio of 125.4% in FY 2024 confirms that earnings are backed by real cash — OCF of $21.47B substantially exceeds net income of $17.12B. CapEx has been declining in absolute terms: from $4.45B (FY 2021) to $3.37B (FY 2024), a 24% reduction while revenue and OCF grew. The FCF/OCF conversion improved to 84.3% as a result. SBC at $0.76B (3.5% of OCF) is low dilution for a large pharmaceutical company.

The 4-year FCF CAGR of 23.3% is exceptional for a company at this scale. It's Keytruda-driven, and that concentration is both the source of the quality and the source of the risk. The same drug that produced $21.47B in OCF in FY 2024 faces patent expiration around 2028, after which biosimilar competition will compress its revenue meaningfully.

Capital Allocation (FY 2024)

Merck is a dividend-first capital allocator. The $7.84B dividend represents 43.3% of FY 2024 FCF — a heavy commitment, but one covered 2.3x by current cash generation. At $9.66B in FY 2021 FCF (the baseline year), coverage was tighter. The buyback program at $1.31B is modest relative to peers who return more via repurchases, suggesting management is preserving flexibility for pipeline acquisitions rather than aggressive share reduction. See FCF yield and dividend investing for how dividend coverage ratios inform payout sustainability.

4-Year FCF Trajectory

FY 2021: $9.66B  ───┐ Baseline year
FY 2022: $14.71B     │ +52% (Keytruda acceleration)
FY 2023: $9.14B      │ -38% (working capital, elevated R&D)
FY 2024: $18.10B ────┘ +98% (record — Keytruda + CapEx decline)

The FY 2023 dip to $9.14B warrants context. OCF fell from $19.09B to $13.01B — not because the business deteriorated, but because elevated working capital usage and higher upfront R&D spending compressed cash in a year of heavy pipeline investment. Revenue grew. The cash flow statement reflected timing. FY 2024's sharp recovery to $21.47B OCF and $18.10B FCF validates that interpretation — the same business that "underperformed" in FY 2023 posted its best-ever cash generation the following year.

Capital Expenditures: Declining

Absolute CapEx declined 24% over four years while revenue grew. The CapEx/OCF ratio hit 15.7% in FY 2024 — the lowest in the series — reflecting a maturing manufacturing capacity base. If this trend continues, the FCF conversion rate improves further. If Merck accelerates acquisition activity (likely for pipeline replacement), CapEx and deal-related spending could step back up.

Investment Quality Assessment

What Works

Keytruda's commercial durability has surprised even optimistic analysts. The drug continues expanding into new indications — lung, bladder, endometrial, MSI-high solid tumors — and its checkpoint inhibitor mechanism has proved applicable across more cancer types than early data suggested. That expanding label has extended the effective revenue window and keeps OCF growing even as the patent expiration date approaches.

The CapEx decline is a genuine positive. Merck's manufacturing base for its established products is built out. Incremental revenue from Keytruda expansion flows through with high cash conversion, explaining why FCF grew 98% on revenue growth that was a fraction of that rate. The 84.3% FCF/OCF conversion in FY 2024 is strong for a pharmaceutical company. For more on pharma FCF dynamics, see our industries with high FCF relevance analysis.

What to Watch

Keytruda's U.S. exclusivity is expected to expire around 2028. The subcutaneous formulation of the drug provides some protection — a harder-to-replicate delivery mechanism than the original IV version — but won't fully offset biosimilar competition. The real question is whether Merck's pipeline can generate a second commercial engine before Keytruda revenues begin declining. So far, the pipeline has produced important but smaller drugs (Gardasil, Winrevair, Capvaxive) rather than a Keytruda-scale replacement. That gap is the central valuation debate.

The Inflation Reduction Act's Medicare drug negotiation provisions directly affect Keytruda pricing. Merck has actively litigated these provisions, but the outcome will shape how quickly post-expiration revenue compression arrives. This is a genuine financial risk and is priced into the stock's multiple — but estimating the magnitude requires tracking regulatory and legal developments, not just financial filings. See red flags in FCF analysis for how revenue concentration creates tail risks.

Forward Outlook

Conclusion

Merck's $18.10B FCF in FY 2024 is one of the strongest absolute cash generation results in global pharmaceuticals. The 28.2% margin, 125% OCF/NI conversion, and declining CapEx all confirm the quality of the number. The dividend — $7.84B, covered 2.3x by FCF — is among the most durable large-cap payouts in the healthcare sector.

The 8/10 FCF Quality Score reflects those genuine strengths. The constraint on a higher score is the Keytruda concentration and patent timeline. Today's cash generation is built on a single drug that faces a defined cliff in 3–5 years. Pipeline success before that cliff matters enormously — it determines whether FY 2024's $18.10B is a baseline or a peak. That's the question that drives MRK's valuation debate, and it won't be resolved by looking at historical cash flow statements alone. Calculate FCF yield for any company using our free tool.

Disclaimer: This analysis is for educational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. You should not make any investment decision based solely on this analysis. Always conduct your own due diligence and consult with a licensed financial advisor before making any investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources: SEC Edgar XBRL filings, Merck & Co. 10-K FY 2021–2024